# Original Article Elevated expression of UHRF1 predicts unfavorable prognosis for patients with hepatocellular carcinoma

Dong Liang, Huanzhou Xue, Yang Yu, Feng Lv, Wei You, Bin Zhang

Department of General Surgery, The People's Hospital of Zhengzhou University (Henan Provincial People's Hospital), Zhengzhou 450003, China

Received May 25, 2015; Accepted June 29, 2015; Epub August 1, 2015; Published August 15, 2015

**Abstract:** Aims: The present study was designed to evaluate the different expression of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) in hepatocellular carcinoma (HCC) tissues and the adjacent normal tissues, further explore the correlation between UHRF1 expression and the prognosis of HCC patients. Methods: The UHRF1 expression at protein level in HCC tissues and the adjacent normal tissues were measured by high performance liquid chromatography (HPLC). Chi-square test was used to estimate the relationship between UHRF1 expression and clinicopathologic characteristics of HCC patients. The overall survival of HCC patients with diverse expression of UHRF1 was measured by Kaplan-Meier analysis. Cox regression analysis was conducted to judge the prognostic value of UHRF1 in HCC patients. Results: The UHRF1 was over-expressed in HCC tissues compared with the adjacent normal tissues according to the outcome of HPLC (P<0.001). Besides, the UHRF1 expression was tightly related to distant metastasis, cancer area, and HBV (P<0.05), but shared no correlation with gender, cirrhosis, and bilirubin (P>0.05). Patients with high UHRF1 expression had a shorter overall survival time than those with low UHRF1 expression (P<0.001). Cox regression analysis showed that UHRF1 was significantly linked with the prognosis of HCC patients (P=0.002, HR=5.807, 95% Cl=1.901-17.742). Conclusion: UHRF1 was over-expressed in HCC tissues compared to the adjacent normal tissues and UHRF1 expression shared significant relevance with distant metastasis, cancer area and HBV. It could be an important and independent prognostic biomarker for HCC patients.


Keywords: Hepatocellular carcinoma, HPLC, UHRF1, prognosis

#### Introduction

Hepatocellular carcinoma (HCC) is a malignant cancer that accounts for the majority of primary liver cancers [1]. HCC is one of the most common cancers and one of the leading causes of cancer-related deaths all over the world [2]. Every year, more than 600,000 patients are diagnosed as HCC and the 5-year survival rate of HCC patients is poor [3]. Virus infection including HBV and HCV has been regarded as the crucial factor for HCC in china [4, 5]. However, the pathogenesis of HCC is still unclear and concealed, the process of HCC is aggressive, invasive and rapid, and the prognosis of HCC is poor with a high mortality because of the diagnosis at an advanced stage [6, 7]. A diagnostic or prognostic marker is useful for the diagnosis or improving the overall survival of patients with HCC. However, the accurate indicators for the diagnosis and prognosis were

scarce. Consequently, it is urgent to develop a novel biomarker for therapy and prognosis of HCC.

Ubiquitinlike with PHD and ring finger domain 1 (UHRF1), which is also known as ICBP90/Np95, encodes multi-functional domain containing proteins with a length of 793 amino acids [8, 9]. UHRF1 could not only regulate the cell proliferation but also maintain DNA methylation and play an important role on the high order of chromatin via the SRA domain and TTD domain [10-15]. It is also considered as an apoptotic-gene and abnormal expressed in various cancers including breast cancer, colorectal cancer, bladder cancer and pancreatic cancer [16-19]. All these studies have suggested that UHRF1 may play an important role in the progression of human cancers. Besides, Zhuo et al. have demonstrated that MEG3 regulates HCC cell proliferation and apoptosis and its over-expression



**Figure 1.** The expression of *UHRF1* in HCC tissues and the adjacent normal tissues were detected by HPLC. The result presented that *UHRF1* expression was strongly increased in HCC tissues compared with the adjacent normal tissues (*P*<0.001).

was thought to be a mechanism underlying DNA hypomethylation in HCC. Meanwhile, *UHRF1* had been proven to be a controlling gene for *MEG3* which might be a prognostic marker for predicting the survival of HCC patients. [20, 21]. However, according to the information we have, the prognostic role of *UHRF1* in HCC has never been reported.

In this study, we aimed at detecting the expression of *UHRF1* in HCC and evaluating whether it could be an innovated prognostic marker for HCC patients.

# Materials and methods

# Patients and specimens

A total of sixty eight HCC patients, including 29 cases infected with HBV, were recruited from Hepatobiliary Department of Internal Medicine in Henan Provincial People's Hospital from 2008 to 2009 in this study. All patients had not received any radiotherapy or chemotherapy before surgery. The study was performed upon the approval of Ethics Committee of Henan Provincial People's Hospital and all patients were asked to sign the informed consents in advance.

The HCC tissues and adjacent tissues were collected from HCC patients and frozen by liquid nitrogen immediately. Then the tissues were stored at -80°C for use. In addition, a 5-years follow-up was conducted with a telephone or questionnaire. The overall survival time of patients was defined from the day of surgery to the day of death. The clinicopathologic characteristics including gender, liver cirrhosis, bilirubin, distant metastasis, cancer area and HBV were recorded. Patients died from unexpected events or other disease were eliminated from our study.

## The detection of UHRF1 protein via high performance liquid chromatography

10 g HCC tissues and the adjacent normal tissues were selected from each specimen, respectively. The homogenate was prepared with the addition of 20 mL methyl cyanides to the tissues and then centrifugated at 4000 r/ min for 10 min. The supernatant was collected and the precipitation was dropped. The extracting solution was affiliated and dried with rotary evaporator, followed by dissolution with 1 mL mobile phase for use. 100 RP  $C_{18}$  column (12×4 mm, 5 µm) was applied and the column temperature was maintained at 35°C. The mobile phase included 20% methyl cyanides, 30% methanol and 50% water with a flow speed of 1 mL/min, and the detection wavelength was at 365 nm. 0.5 g UHRF1 protein was dissolved with mobile phase in a 10 mL volumetric flask and used as standard solution for the HPLC.

# Statistical analysis

All data were analyzed by SPSS 18.0 software. The difference of *UHRF1* protein expression in HCC tissues and adjacent tissues was estimated by students *t* test. While the relationship between *UHRF1* protein expression and clinicopathologic characteristics was estimated by Chi-square test. Kaplan-Meier analysis was adopted to delineate the overall survival time of HCC patients with different *UHRF1* protein expression. The prognostic value of *UHRF1* was evaluated by Cox regression analysis. It was considered to be significant different when *P* value was less than 0.05.

# Results

# Up-regulation of UHRF1 protein in HCC tissues

The UHRF1 protein expression in HCC tissues and adjacent normal tissues was determined by HPLC method. As shown in **Figure 1**, the concentration of UHRF1 protein in HCC tissues was  $66.98\pm13.46$  (mean  $\pm$  SD), which was significantly higher than that in the adjacent normal tissues ( $36.26\pm9.72$ ), indicating that UHRF1

Characteristics	Case (n)	UHRF1 protein Expression		2	
		High (n)	Low (n)	X <sup>2</sup>	P value
Gender				0.180	0.671
Male	35	25	10		
Female	33	22	11		
Liver cirrhosis				1.240	0.265
Yes	36	27	9		
No	32	20	12		
Bilirubin (µmol/L)				1.722	0.189
≤17.1	34	21	13		
>17.1	34	26	8		
Distant metastasis				4.607	0.032
Yes	39	31	8		
No	29	16	13		
Cancer area (cm <sup>2</sup> )				4.168	0.041
≤10	36	21	15		
>10	32	26	6		
HBV				4.408	0.036
Yes	29	24	5		
No	39	23	16		

**Table 1.** Correlation between UHRF1 expression and clinicopathologic characteristics

was increased in HCC tissues (*P*<0.001). This might intimate that *UHRF1* was an oncogene in HCC.

Association between UHRF1 protein expression and clinicopathologic characteristics of HCC patients

Further investigations were performed to evaluate the association between *UHRF1* expression and the clinicopathologic characteristics of HCC patients. All the enrolled patients were divided into two groups: the high group with *UHRF1* protein expression of more than 42.3, and the low group with *UHRF1* protein expression of less than or equal to 42.3. It was confirmed that *UHRF1* expression was significantly related to distant metastasis (P=0.032), cancer area (P=0.041), and HBV (P=0.036) (**Table 1**). However, there was no statistical difference between *UHRF1* protein expression and gender, cirrhosis as well as the concentration of bilirubin (P>0.05).


### Elevated protein expression of UHRF1 was related to poor prognosis of HCC patients

A follow-up ranged from 0 to 60 months was adapted to deeply research the prognostic value of *UHRF1* in HCC patients. During the follow-up, 33 (70.2%) patients in high UHRF1 protein expression group died, while only 4 (19.0%) died among those with low UHRF1 protein expression. Kaplan-Meier analysis showed that the overall survival time of patients with high UHRF1 protein expression was significantly shorter than those with low UHRF1 protein expression (Figure 2, log rank test, P=0.000). Cox regression analysis manifested that there was significant correlation between UHRF1 protein expression and the prognosis of HCC patients (Table 2, P=0.002, HR=5.807, 95% CI=1.901-17.742). The results indicated that UHRF1 could act as an independent prognostic biomarker for HCC patients.

# Discussion

HCC is of high malignancy and rapid development with a short average survival time [22]. Early HCC has no obvious symptoms thus patients are often diagnosed with advanced stage. The 5-year survival rate of HCC is only 14% [23]. Therapies for HCC in clinical are predominantly surgery, radiotherapy and chemotherapy. However, these therapies have weak effects on advanced stage patients and the prognosis of HCC patients was poor [24]. Therefore, early discovery, early diagnosis and early treatment are of urgent needs for HCC patients. Many researchers have engaged in finding some molecules that can be candidate biomarkers for therapy and prognosis of HCC and various biomarkers had already been found such as AFP, miRNA and IncRNA [25-28].

*UHRF1* encodes a series of a subfamily of ringfinger type E3 ubiquitin ligases. The protein can bind to specific DNA sequences to regulate chromatin structure and gene expression. Recently, much attention from investigators has been focused on the relationship between *UHRF1* expression and various cancers. A quantity of reports manifested that overexpression of *UHRF1* was observed in many kinds of cancer. For example, Cui et al. found



**Figure 2.** The overall survival of HCC patients was evaluated by Kaplan-Meier analysis. The result indicated that the survival time of patients with high *UHRF1* protein expression was shorter than those with low *UHRF1* protein expression (P=0.000).

Table 2. Multivariate analysis of UHRF1 protein expression and
clinicopathologic characteristics in the prognostic of HCC

Clinical characteristics	P value	HR	95% CI
Bilirubin	0.346	0.713	0.353-1.441
Cancer area	0.250	1.598	0.719-3.551
HBV	0.157	1.725	0.811-3.668
High UHRF1 expression	0.002	5.807	1.901-17.742
Low UHRF1 expression	-	-	-

that the up-regulated UHRF1 in pancreatic cancer cells not only be an oncogene, but also could promote the cell growth, migration and metastasis [29]. In bladder cancer although UHRF1 expression was also increased, but it played a role in inducing cell invasion [30]. The over-expression of UHRF1 was also discovered in lung cancer, and it played an important role in the diagnosis of this cancer [31]. In addition, UHRF1 over-expression was observed in HCC in previous study, but the relationship between UHRF1 expression and clinicopathological characteristics as well as the prognostic value of *UHRF1* in HCC patients was still unclear.

In the present study, we validated the expression level of UHRF1 in HCC by HPLC. The over-expression of UHRF1 was observed in HCC cases, especially in HBV infected cases, which was accordant with the previous description [21]. So we inferred that UHRF1 might be an oncogene of HCC. Moreover, previous studies have found that UHRF1 expression level was linked to the presence of lymph node metastasis, distal metastasis, and T stage [17, 31]. Yang et al. [18] have shown that in bladder cancer, UHRF1 expression was positively related with tumor grade. Thus in our study, we analyzed the relationship between UHRF1 expression and clinicopathologic characteristics in HCC. Distant metastasis, cancer area and HBV infection were proved to be influential factors for the protein expression of UHRF1. Based on the result, UHRF1 was suggested to be a participator in the development of HCC.

The prognostic value of *UHRF1* was studied in several cancers including bladder cancer [18], lung cancer [31], and prostate cancer

[32]. Furthermore, in bladder cancer [18] and lung cancer [31] patients, *UHRF1* could be used as an independent prognostic biomarker. However, the potential role of *UHRF1* in the prognosis of HCC is still unclear, and it is necessary to explore an effective prognostic marker for HCC patients. Thus we estimated the prognostic value of *UHRF1* in HCC. The overall survival time of patients with high *UHRF1* expression was shorter than those with low expression according to Kaplan-Meier analysis which manifested that *UHRF1* was related to the prognosis of HCC. Hence, the multivariate analysis was performed and the result exhibited that high UHRF1 expression increased the risk of HCC. The UHRF1 was a vital factor for the prognosis of HCC and would be an independent prognostic biomarker for HCC patients.

In conclusion, combing with the previous findings, we have verified that the expression of *UHRF1* was increased in HCC and it could act as a potential prognostic indicator for HCC patients. However, the mechanism of *UHRF1* on HCC remains unclear which needs to be further investigated.

#### Disclosure of conflict of interest

None.

Address correspondence to: Dr. Huanzhou Xue, Department of General Surgery, The People's Hospital of Zhengzhou University (Henan Provincial People's Hospital), Zhengzhou 450003, China. E-mail: xuanhuanzho@126.com

#### References

- [1] Amaddeo G, Guichard C, Imbeaud S and Zucman-Rossi J. Next-generation sequencing identified new oncogenes and tumor suppressor genes in human hepatic tumors. Oncoimmunology 2012; 1: 1612-1613.
- [2] Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
- [3] Jhunjhunwala S, Jiang Z, Stawiski EW, Gnad F, Liu J, Mayba O, Du P, Diao J, Johnson S, Wong KF, Gao Z, Li Y, Wu TD, Kapadia SB, Modrusan Z, French DM, Luk JM, Seshagiri S and Zhang Z. Diverse modes of genomic alteration in hepatocellular carcinoma. Genome Biol 2014; 15: 436.
- [4] Yang P, Li QJ, Feng Y, Zhang Y, Markowitz GJ, Ning S, Deng Y, Zhao J, Jiang S, Yuan Y, Wang HY, Cheng SQ, Xie D and Wang XF. TGF-betamiR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell 2012; 22: 291-303.
- [5] Willimsky G, Schmidt K, Loddenkemper C, Gellermann J and Blankenstein T. Virusinduced hepatocellular carcinomas cause antigen-specific local tolerance. J Clin Invest 2013; 123: 1032-1043.
- [6] Sherman M. Recurrence of hepatocellular carcinoma. N Engl J Med 2008; 359: 2045-2047.
- [7] Yamashita T and Wang XW. Cancer stem cells in the development of liver cancer. J Clin Invest 2013; 123: 1911-1918.

- [8] Luo T, Cui S, Bian C and Yu X. Uhrf2 is important for DNA damage response in vascular smooth muscle cells. Biochem Biophys Res Commun 2013; 441: 65-70.
- [9] Chen H, Zhang C, Sheng Y, Yao S, Liu Z and Zhang T. Frequent SOCS3 and 30ST2 promoter methylation and their epigenetic regulation in endometrial carcinoma. Am J Cancer Res 2015; 5: 180-190.
- [10] Fang L, Shanqu L, Ping G, Ting H, Xi W, Ke D, Min L, Junxia W and Huizhong Z. Gene therapy with RNAi targeting UHRF1 driven by tumorspecific promoter inhibits tumor growth and enhances the sensitivity of chemotherapeutic drug in breast cancer in vitro and in vivo. Cancer Chemother Pharmacol 2012; 69: 1079-1087.
- [11] Karagianni P, Amazit L, Qin J and Wong J. ICBP90, a novel methyl K9 H3 binding protein linking protein ubiquitination with heterochromatin formation. Mol Cell Biol 2008; 28: 705-717.
- [12] Rothbart SB, Dickson BM, Ong MS, Krajewski K, Houliston S, Kireev DB, Arrowsmith CH and Strahl BD. Multivalent histone engagement by the linked tandem Tudor and PHD domains of UHRF1 is required for the epigenetic inheritance of DNA methylation. Genes Dev 2013; 27: 1288-1298.
- [13] Bostick M, Kim JK, Esteve PO, Clark A, Pradhan S and Jacobsen SE. UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science 2007; 317: 1760-1764.
- [14] Rottach A, Frauer C, Pichler G, Bonapace IM, Spada F and Leonhardt H. The multi-domain protein Np95 connects DNA methylation and histone modification. Nucleic Acids Res 2010; 38: 1796-1804.
- [15] Unoki M, Nishidate T and Nakamura Y. ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain. Oncogene 2004; 23: 7601-7610.
- [16] Geng Y, Gao Y, Ju H and Yan F. Diagnostic and prognostic value of plasma and tissue ubiquitin-like, containing PHD and RING finger domains 1 in breast cancer patients. Cancer Sci 2013; 104: 194-199.
- [17] Wang F, Yang YZ, Shi CZ, Zhang P, Moyer MP, Zhang HZ, Zou Y and Qin HL. UHRF1 promotes cell growth and metastasis through repression of p16 (ink(4)a) in colorectal cancer. Ann Surg Oncol 2012; 19: 2753-2762.
- [18] Yang GL, Zhang LH, Bo JJ, Chen HG, Cao M, Liu DM and Huang YR. UHRF1 is associated with tumor recurrence in non-muscle-invasive bladder cancer. Med Oncol 2012; 29: 842-847.
- [19] Crnogorac-Jurcevic T, Gangeswaran R, Bhakta V, Capurso G, Lattimore S, Akada M, Sunamura M, Prime W, Campbell F, Brentnall TA, Costello

E, Neoptolemos J and Lemoine NR. Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterology 2005; 129: 1454-1463.

- [20] Zhuo H, Tang J, Lin Z, Jiang R, Zhang X, Ji J, Wang P and Sun B. The aberrant expression of MEG3 regulated by UHRF1 predicts the prognosis of hepatocellular carcinoma. Mol Carcinog 2015; [Epub ahead of print].
- [21] Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A, Fiel MI, Chen X, Kojima K, Thung S, Bronson RT, Lachenmayer A, Revill K, Alsinet C, Sachidanandam R, Desai A, SenBanerjee S, Ukomadu C, Llovet JM and Sadler KC. UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma. Cancer Cell 2014; 25: 196-209.
- [22] Bosch FX, Ribes J, Diaz M and Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127: S5-S16.
- [23] Cao K, Lu C, Han S, Zou Q, Li J, Xie D, He S, Yu L, Zhou J, Peng X and Cao P. Expression of Girdin in primary hepatocellular carcinoma and its effect on cell proliferation and invasion. Int J Clin Exp Pathol 2015; 8: 551-559.
- [24] Hao K, Luk JM, Lee NP, Mao M, Zhang C, Ferguson MD, Lamb J, Dai H, Ng IO, Sham PC and Poon RT. Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters. BMC Cancer 2009; 9: 389.
- [25] Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S, Hainaut P, Marrero JA and Beretta L. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 2012; 55: 483-490.
- [26] Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z, Wang JF, Zhang Z, Lu S, Huang X, Wang Z, Qiu S, Wang X, Yang G, Sun H, Tang Z, Wu Y, Zhu H and Fan J. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol 2011; 29: 4781-4788.

- [27] Yamashita T, Kitao A, Matsui O, Hayashi T, Nio K, Kondo M, Ohno N, Miyati T, Okada H, Mizukoshi E, Honda M, Nakanuma Y, Takamura H, Ohta T, Nakamoto Y, Yamamoto M, Takayama T, Arii S, Wang X and Kaneko S. Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinoma. Hepatology 2014; 60: 1674-1685.
- [28] Quagliata L, Matter MS, Piscuoglio S, Arabi L, Ruiz C, Procino A, Kovac M, Moretti F, Makowska Z, Boldanova T, Andersen JB, Hammerle M, Tornillo L, Heim MH, Diederichs S, Cillo C and Terracciano LM. Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. Hepatology 2014; 59: 911-923.
- [29] Cui L, Chen J, Zhang Q, Wang X, Qu J, Zhang J and Dang S. Up-regulation of UHRF1 by oncogenic Ras promoted the growth, migration, and metastasis of pancreatic cancer cells. Mol Cell Biochem 2015; 400: 223-232.
- [30] Zhang Y, Huang Z, Zhu Z, Zheng X, Liu J, Han Z and Ma X. Upregulated UHRF1 promotes bladder cancer cell invasion by epigenetic silencing of KiSS1. PLoS One 2014; 9: e104252.
- [31] Unoki M, Daigo Y, Koinuma J, Tsuchiya E, Hamamoto R and Nakamura Y. UHRF1 is a novel diagnostic marker of lung cancer. Br J Cancer 2010; 103: 217-222.
- [32] Babbio F, Pistore C, Curti L, Castiglioni I, Kunderfranco P, Brino L, Oudet P, Seiler R, Thalman GN, Roggero E, Sarti M, Pinton S, Mello-Grand M, Chiorino G, Catapano CV, Carbone GM and Bonapace IM. The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression. Oncogene 2012; 31: 4878-4887.